Botox Owner Allergan to Buy Maker of Double-Chin Treatment

Allergan agreed to buy Kythera Biopharmaceuticals and its newly approved double-chin treatment in a $2.1 billion deal that aims to plump up the Botox maker’s lineup of cosmetic medicines.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news